Sprinkle of hope: new formulation tested for Toddlers' tumors
NCT ID NCT05309668
Summary
This study is testing a new 'sprinkle' granule form of a drug called selumetinib for very young children (ages 1 to 7) with neurofibromatosis type 1 (NF1) who have painful or problematic tumors that cannot be removed by surgery. The main goals are to find the right dose for this age group, understand how the body processes the drug, and check its safety. Researchers will also look for early signs that the treatment might help shrink these tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROFIBROMATOSIS TYPE 1 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Akron, Ohio, 44308, United States
-
Research Site
Philadelphia, Pennsylvania, 19104, United States
-
Research Site
Houston, Texas, 77030, United States
-
Research Site
Richmond, Virginia, 23219, United States
-
Research Site
Hamburg, 20246, Germany
-
Research Site
München, 80337, Germany
-
Research Site
Tübingen, 72076, Germany
-
Research Site
Milan, 20133, Italy
-
Research Site
Rome, 00165, Italy
-
Research Site
Nagoya, 466-8560, Japan
-
Research Site
Setagaya City, 157-8535, Japan
-
Research Site
Rotterdam, 3015 GD, Netherlands
-
Research Site
Moscow, 119620, Russia
-
Research Site
Moscow, 125412, Russia
-
Research Site
Barcelona, 08950, Spain
-
Research Site
Madrid, Spain
Conditions
Explore the condition pages connected to this study.